Shield Therapeutics issued a February trading statement showing excellent US H122 vs H222 sales growth of 97% and confirmed a successful funding round of $31.7mln plus the $5mln Viatris deal fee.Shield delivered record US sales of 25,200 prescriptions in 2022, with 16,724 of these sales (66%) in H2
13 Feb 2023
Trading update confirms strong US sales growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trading update confirms strong US sales growth
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.6m
- Published:
13 Feb 2023 -
Author:
Robin Davison | John Savin PhD | Daniel Appiah -
Pages:
3
Shield Therapeutics issued a February trading statement showing excellent US H122 vs H222 sales growth of 97% and confirmed a successful funding round of $31.7mln plus the $5mln Viatris deal fee.Shield delivered record US sales of 25,200 prescriptions in 2022, with 16,724 of these sales (66%) in H2